patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_777580 | REC_0004201 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 5.2 | 69 | female | 1 | 8 | 5.1 | 4 | osimertinib 80 mg daily | 14 | false | MSS | 2026-03-15T05:35:57.884543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365973 | REC_0004202 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 7.9 | 62 | female | 0 | 24 | 6.7 | 4 | osimertinib 80 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:57.884780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459058 | REC_0004203 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 14.9 | 49 | female | 0 | 18 | 5 | 2 | alectinib 600 mg BID | 11.1 | true | MSS | 2026-03-15T05:35:57.885020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110417 | REC_0004204 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 15.1 | 79 | female | 2 | 10 | 7.3 | 3 | pembrolizumab 200 mg q3w | 20.6 | true | MSI-H | 2026-03-15T05:35:57.885250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936242 | REC_0004205 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 9.8 | 73 | female | 2 | 1 | 4.8 | 5 | sotorasib 960 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:57.885479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686823 | REC_0004206 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 7.4 | 60 | female | 1 | 10 | 3.9 | 2 | osimertinib 80 mg daily | 20.6 | true | MSS | 2026-03-15T05:35:57.885709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970679 | REC_0004207 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 6.2 | 56 | male | 1 | 67 | 4 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.6 | false | MSS | 2026-03-15T05:35:57.885943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853850 | REC_0004208 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.4 | 71 | female | 1 | 7 | 6.2 | 6 | entrectinib 600 mg daily | 12.4 | false | MSI-H | 2026-03-15T05:35:57.886184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893343 | REC_0004209 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 17.1 | 77 | male | 2 | 20 | 3.6 | 1 | entrectinib 600 mg daily | 24.6 | false | MSS | 2026-03-15T05:35:57.886422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955275 | REC_0004210 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 15 | 69 | female | 1 | 9 | 5.4 | 4 | osimertinib 80 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:57.886655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165588 | REC_0004211 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 8.1 | 67 | female | 1 | 12 | 5.5 | 1 | osimertinib 80 mg daily | 23 | true | MSS | 2026-03-15T05:35:57.886881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697807 | REC_0004212 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.6 | 62 | female | 0 | 33 | 6.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.5 | true | MSS | 2026-03-15T05:35:57.887111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883094 | REC_0004213 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 11.2 | 62 | male | 0 | 11 | 3.6 | 2 | osimertinib 80 mg daily | 26.6 | false | MSS | 2026-03-15T05:35:57.887421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376822 | REC_0004214 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 13.6 | 76 | female | 2 | 10 | 5.4 | 5 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:35:57.887660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111817 | REC_0004215 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 6.9 | 74 | female | 1 | 45 | 6.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.9 | true | MSS | 2026-03-15T05:35:57.887889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530499 | REC_0004216 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 6.3 | 79 | female | 0 | 17 | 6.4 | 1 | osimertinib 80 mg daily | 18.5 | true | MSS | 2026-03-15T05:35:57.888154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603190 | REC_0004217 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 11.2 | 65 | male | 1 | 21 | 6.3 | 2 | entrectinib 600 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:57.888397+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253798 | REC_0004218 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 10.7 | 72 | female | 1 | 10 | 4.4 | 6 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:57.888629+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252064 | REC_0004219 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 9.5 | 65 | male | 1 | 16 | 3.8 | 5 | entrectinib 600 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:57.888862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866851 | REC_0004220 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 12.4 | 82 | female | 0 | 12 | 5.4 | 4 | entrectinib 600 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:57.889097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_953183 | REC_0004221 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 12.7 | 60 | male | 0 | 11 | 6.3 | 5 | osimertinib 80 mg daily | 7.6 | true | MSS | 2026-03-15T05:35:57.889339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801768 | REC_0004222 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 11.2 | 79 | female | 2 | 15 | 4.2 | 5 | entrectinib 600 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:57.889570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728097 | REC_0004223 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 14.7 | 71 | female | 1 | 22 | 5 | 1 | alectinib 600 mg BID | 9.5 | false | MSI-H | 2026-03-15T05:35:57.889802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463940 | REC_0004224 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5.7 | 77 | female | 2 | 47 | 5.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.9 | false | MSS | 2026-03-15T05:35:57.890033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989687 | REC_0004225 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 10 | 66 | female | 1 | 6 | 6.5 | 2 | pembrolizumab 200 mg q3w | 23.2 | false | MSI-H | 2026-03-15T05:35:57.890273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647206 | REC_0004226 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 11 | 57 | male | 0 | 3 | 5.3 | 1 | osimertinib 80 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:35:57.890631+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576614 | REC_0004227 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.7 | 69 | female | 1 | 19 | 6.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 15.2 | false | MSS | 2026-03-15T05:35:57.890913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363990 | REC_0004228 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 32 | 12.4 | 50 | male | 0 | 10 | 5.5 | 2 | pembrolizumab 200 mg q3w | 17.2 | false | MSI-H | 2026-03-15T05:35:57.891166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363240 | REC_0004229 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 15.2 | 62 | female | 1 | 19 | 5.3 | 6 | alectinib 600 mg BID | 14 | false | MSI-H | 2026-03-15T05:35:57.891412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772796 | REC_0004230 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 34 | 11.5 | 76 | female | 1 | 16 | 6.7 | 0 | entrectinib 600 mg daily | 35.8 | true | MSS | 2026-03-15T05:35:57.891644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762980 | REC_0004231 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.1 | 72 | female | 2 | 5 | 4.5 | 6 | alectinib 600 mg BID | 12.6 | false | MSS | 2026-03-15T05:35:57.891880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693611 | REC_0004232 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.8 | 63 | male | 1 | 18 | 5.6 | 3 | osimertinib 80 mg daily | 9.5 | false | MSI-H | 2026-03-15T05:35:57.892198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423629 | REC_0004233 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 9.7 | 60 | female | 1 | 4 | 3.3 | 9 | alectinib 600 mg BID | 6.4 | false | MSS | 2026-03-15T05:35:57.892451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204876 | REC_0004234 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 7.6 | 60 | female | 1 | 7 | 4.9 | 5 | osimertinib 80 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:57.892688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861413 | REC_0004235 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.3 | 73 | male | 1 | 13 | 5.2 | 2 | pembrolizumab 200 mg q3w | 17.2 | true | MSS | 2026-03-15T05:35:57.892921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164313 | REC_0004236 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 15.4 | 77 | female | 2 | 13 | 6.8 | 2 | alectinib 600 mg BID | 22.4 | true | MSS | 2026-03-15T05:35:57.893162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422654 | REC_0004237 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 10.3 | 73 | female | 0 | 14 | 4.7 | 2 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:35:57.893396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936730 | REC_0004238 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.2 | 68 | female | 0 | 9 | 5.6 | 4 | osimertinib 80 mg daily | 10.1 | false | MSS | 2026-03-15T05:35:57.893628+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924996 | REC_0004239 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 6 | 86 | female | 1 | 8 | 4.2 | 7 | osimertinib 80 mg daily | 7.2 | true | MSS | 2026-03-15T05:35:57.893956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207994 | REC_0004240 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 5.9 | 71 | female | 0 | 15 | 6.3 | 2 | sotorasib 960 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:57.894187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546953 | REC_0004241 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 13 | 6.2 | 71 | female | 1 | 15 | 6.2 | 0 | pembrolizumab 200 mg q3w | 21.3 | true | MSS | 2026-03-15T05:35:57.894417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300121 | REC_0004242 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 39 | 8.1 | 76 | female | 2 | 22 | 3.9 | 1 | sotorasib 960 mg daily | 26.8 | false | MSS | 2026-03-15T05:35:57.894648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_163796 | REC_0004243 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 18.9 | 73 | female | 2 | 4 | 4.5 | 1 | pembrolizumab 200 mg q3w | 14.3 | false | MSI-H | 2026-03-15T05:35:57.894882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890214 | REC_0004244 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 18 | 15.1 | 70 | female | 1 | 13 | 4.8 | 2 | pembrolizumab 200 mg q3w | 17.4 | true | MSS | 2026-03-15T05:35:57.895130+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506719 | REC_0004245 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 10.5 | 65 | female | 1 | 15 | 5.5 | 6 | entrectinib 600 mg daily | 4.2 | false | MSS | 2026-03-15T05:35:57.895367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898441 | REC_0004246 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.4 | 59 | male | 1 | 52 | 7.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.9 | false | MSS | 2026-03-15T05:35:57.895599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539732 | REC_0004247 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 13.7 | 52 | female | 0 | 22 | 8 | 9 | osimertinib 80 mg daily | 4.8 | true | MSI-H | 2026-03-15T05:35:57.895837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990728 | REC_0004248 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 34 | 5.9 | 67 | female | 0 | 52 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.6 | false | MSS | 2026-03-15T05:35:57.896169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589933 | REC_0004249 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 3.7 | 72 | female | 4 | 22 | 4.3 | 1 | pembrolizumab 200 mg q3w | 17.2 | false | MSS | 2026-03-15T05:35:57.896417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143508 | REC_0004250 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 16 | 61 | female | 0 | 21 | 4.7 | 6 | osimertinib 80 mg daily | 9 | true | MSS | 2026-03-15T05:35:57.896660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379570 | REC_0004251 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 17.2 | 66 | female | 0 | 21 | 5.7 | 6 | osimertinib 80 mg daily | 10.1 | false | MSS | 2026-03-15T05:35:57.896897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547041 | REC_0004252 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 12.1 | 56 | male | 0 | 5 | 5.6 | 5 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:57.897211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984710 | REC_0004253 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 16.1 | 82 | male | 2 | 11 | 5.6 | 7 | alectinib 600 mg BID | 10.7 | false | MSS | 2026-03-15T05:35:57.897457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543897 | REC_0004254 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 19.9 | 82 | female | 1 | 22 | 4.6 | 10 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:57.897690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766745 | REC_0004255 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.3 | 68 | female | 0 | 12 | 4.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.6 | true | MSS | 2026-03-15T05:35:57.897924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782293 | REC_0004256 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 11.7 | 65 | male | 0 | 18 | 5.5 | 6 | alectinib 600 mg BID | 4.4 | false | MSI-H | 2026-03-15T05:35:57.898162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417198 | REC_0004257 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 15.9 | 72 | female | 1 | 12 | 5.1 | 6 | alectinib 600 mg BID | 12.4 | false | MSS | 2026-03-15T05:35:57.898395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697083 | REC_0004258 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 22 | 15.4 | 72 | female | 2 | 35 | 6.4 | 0 | alectinib 600 mg BID | 33.1 | true | MSI-H | 2026-03-15T05:35:57.898625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401706 | REC_0004259 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 10 | 68 | female | 0 | 51 | 4.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.2 | false | MSI-H | 2026-03-15T05:35:57.898857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201089 | REC_0004260 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 3 | 56 | female | 0 | 6 | 3.2 | 5 | alectinib 600 mg BID | 8.4 | false | MSS | 2026-03-15T05:35:57.899088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910814 | REC_0004261 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.4 | 54 | female | 0 | 58 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:57.899325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960740 | REC_0004262 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 20.2 | 64 | male | 0 | 15 | 6.4 | 1 | sotorasib 960 mg daily | 30.7 | false | MSS | 2026-03-15T05:35:57.899563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830234 | REC_0004263 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 17.4 | 59 | female | 1 | 7 | 6 | 4 | osimertinib 80 mg daily | 6.4 | true | MSI-H | 2026-03-15T05:35:57.899806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871627 | REC_0004264 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 10.2 | 67 | male | 1 | 25 | 5.4 | 6 | pembrolizumab 200 mg q3w | 9.6 | true | MSI-H | 2026-03-15T05:35:57.900049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442393 | REC_0004265 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.3 | 74 | female | 1 | 10 | 5 | 3 | sotorasib 960 mg daily | 16.3 | false | MSS | 2026-03-15T05:35:57.900417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646232 | REC_0004266 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 16.9 | 51 | female | 0 | 8 | 5.2 | 1 | sotorasib 960 mg daily | 27.9 | false | MSI-H | 2026-03-15T05:35:57.900674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859702 | REC_0004267 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 3.1 | 89 | female | 2 | 19 | 5.6 | 9 | entrectinib 600 mg daily | 14 | false | MSS | 2026-03-15T05:35:57.900914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864191 | REC_0004268 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 8.2 | 72 | female | 1 | 48 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:35:57.901168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903942 | REC_0004269 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.7 | 78 | female | 1 | 16 | 6.2 | 6 | osimertinib 80 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:57.901422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245866 | REC_0004270 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 17.1 | 71 | female | 1 | 17 | 5.8 | 6 | sotorasib 960 mg daily | 15.7 | true | MSI-H | 2026-03-15T05:35:57.901667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818697 | REC_0004271 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 7.3 | 57 | male | 1 | 13 | 5.6 | 1 | sotorasib 960 mg daily | 20.8 | true | MSS | 2026-03-15T05:35:57.901915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313517 | REC_0004272 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 15.2 | 62 | male | 1 | 11 | 8.3 | 7 | osimertinib 80 mg daily | 20.8 | false | MSS | 2026-03-15T05:35:57.902161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737685 | REC_0004273 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 14.7 | 75 | female | 2 | 16 | 6.5 | 4 | osimertinib 80 mg daily | 8.5 | true | MSS | 2026-03-15T05:35:57.902398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829106 | REC_0004274 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 7.3 | 70 | male | 1 | 17 | 4.6 | 1 | pembrolizumab 200 mg q3w | 20.9 | true | MSS | 2026-03-15T05:35:57.902640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301819 | REC_0004275 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 9.7 | 65 | male | 0 | 10 | 4.5 | 7 | entrectinib 600 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:57.902875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737044 | REC_0004276 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5 | 70 | female | 2 | 34 | 4.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:35:57.903109+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695965 | REC_0004277 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 14.2 | 73 | female | 2 | 5 | 3.2 | 1 | osimertinib 80 mg daily | 8.1 | false | MSI-H | 2026-03-15T05:35:57.903347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865577 | REC_0004278 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.9 | 66 | female | 0 | 69 | 4.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.8 | true | MSS | 2026-03-15T05:35:57.903686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493995 | REC_0004279 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.3 | 77 | female | 2 | 8 | 7.6 | 5 | entrectinib 600 mg daily | 9 | false | MSS | 2026-03-15T05:35:57.903936+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645104 | REC_0004280 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 13.1 | 61 | male | 1 | 6 | 6.9 | 9 | sotorasib 960 mg daily | 14.4 | true | MSS | 2026-03-15T05:35:57.904252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333892 | REC_0004281 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 7.4 | 59 | male | 0 | 10 | 4.6 | 4 | pembrolizumab 200 mg q3w | 10.3 | true | MSS | 2026-03-15T05:35:57.904537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272726 | REC_0004282 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 31 | 12.5 | 74 | female | 2 | 18 | 6.2 | 0 | sotorasib 960 mg daily | 37.3 | false | MSI-H | 2026-03-15T05:35:57.904802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212682 | REC_0004283 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 18 | 12.9 | 59 | female | 0 | 7 | 6.7 | 0 | entrectinib 600 mg daily | 36.3 | false | MSI-H | 2026-03-15T05:35:57.905062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963506 | REC_0004284 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 15.1 | 53 | female | 0 | 12 | 5.5 | 6 | alectinib 600 mg BID | 20.5 | false | MSI-H | 2026-03-15T05:35:57.905321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867913 | REC_0004285 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 7.6 | 63 | male | 1 | 21 | 5.4 | 7 | pembrolizumab 200 mg q3w | 13.3 | true | MSS | 2026-03-15T05:35:57.905587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690283 | REC_0004286 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 10.5 | 56 | male | 0 | 17 | 4.5 | 6 | sotorasib 960 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:57.905866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979898 | REC_0004287 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 17.7 | 59 | male | 0 | 14 | 5.7 | 5 | sotorasib 960 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:57.906122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979285 | REC_0004288 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.6 | 72 | female | 3 | 105 | 7.6 | 5 | pembrolizumab 200 mg q3w | 7.5 | false | MSS | 2026-03-15T05:35:57.906362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324283 | REC_0004289 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7.7 | 76 | female | 2 | 35 | 6.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 12.4 | true | MSS | 2026-03-15T05:35:57.906605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875492 | REC_0004290 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 3.4 | 75 | female | 2 | 33 | 6.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:57.906844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858027 | REC_0004291 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 11.3 | 67 | female | 0 | 9 | 6.3 | 6 | osimertinib 80 mg daily | 13.4 | true | MSS | 2026-03-15T05:35:57.907211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159442 | REC_0004292 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 9.9 | 77 | female | 1 | 12 | 5.6 | 6 | entrectinib 600 mg daily | 13.9 | true | MSS | 2026-03-15T05:35:57.907455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776125 | REC_0004293 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 12.4 | 51 | female | 0 | 20 | 4.7 | 3 | alectinib 600 mg BID | 17.5 | false | MSI-H | 2026-03-15T05:35:57.907694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212855 | REC_0004294 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 7.5 | 70 | female | 3 | 23 | 6 | 7 | osimertinib 80 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:57.907924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932008 | REC_0004295 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 11.8 | 64 | male | 0 | 13 | 6.7 | 5 | osimertinib 80 mg daily | 6.6 | false | MSS | 2026-03-15T05:35:57.908237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871322 | REC_0004296 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 14 | 9.4 | 58 | female | 1 | 15 | 2.8 | 3 | sotorasib 960 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:57.908482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907393 | REC_0004297 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 14.8 | 55 | male | 0 | 21 | 7.7 | 2 | alectinib 600 mg BID | 13.1 | true | MSI-H | 2026-03-15T05:35:57.908725+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360408 | REC_0004298 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 15.3 | 81 | female | 1 | 16 | 3.9 | 6 | sotorasib 960 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:57.908964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290987 | REC_0004299 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 8.4 | 66 | female | 1 | 20 | 6.6 | 7 | pembrolizumab 200 mg q3w | 15.5 | false | MSS | 2026-03-15T05:35:57.909194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402370 | REC_0004300 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 7.2 | 64 | male | 0 | 16 | 4.5 | 2 | pembrolizumab 200 mg q3w | 23 | true | MSS | 2026-03-15T05:35:57.909433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.